Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Milojevic, Aleksandar (57219864196)"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Clinical Impact of Patient-Prosthesis Mismatch After Aortic Valve Replacement With a Mechanical or Biological Prosthesis
    (2023)
    Matkovic, Milos (57113361300)
    ;
    Aleksic, Nemanja (57209310510)
    ;
    Bilbija, Ilija (57113576000)
    ;
    Antic, Ana (57224966433)
    ;
    Lazovic, Jelena Milin (6507693272)
    ;
    Cubrilo, Marko (57209307258)
    ;
    Milojevic, Aleksandar (57219864196)
    ;
    Zivkovic, Igor (57192104502)
    ;
    Putnik, Svetozar (16550571800)
    Background: Patient-prosthesis mismatch (PPM) may impair functional capacity and survival after aortic valve replacement. This study aimed to investigate the impact of PPM on long-term survival and quality of life after mechanical and biological aortic valve replacement. Methods: This study included 595 consecutive patients who had undergone isolated aortic valve replace-ment. Patients were divided into 2 groups according to prosthesis type. The baseline and operative charac-teristics, survival rates, complications, and quality of life of the groups with and without PPM were compared for up to 6 years. The PPM calculation was performed using the effective orifice area value provided by the manufacturer divided by the patient’s body surface area. Results: The moderate to severe PPM rates were 69.8% and 3.7% after biological and mechanical prosthesis implantation, respectively. Mean survival for patients in the biological group who had PPM was statistically significantly shorter (50.2 months [95% CI, 45.2-55.3]) than for patients in the biological group without PPM (60.1 months [95% CI, 55.7-64.4]; P = .04). In the mechanical prosthesis group, there was no difference in mean survival between the subgroup with PPM (66.6 months [95% CI, 58.3-74.9]) and the subgroup without PPM (64.9 months [95% CI, 62.6-67.2]; P = .50). A quality-of-life questionnaire’s scores did not differ between the groups. Conclusion: Mismatch is common after biological valve implantation and statistically significantly affects long-term survival and quality of life. If the risk of PPM after implantation of a biological prosthesis is sus-pected, adopting strategies to avoid PPM at the time of surgery is warranted. © 2023, Texas Heart Institute. All rights reserved.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    The routine use of platelet function tests in elective coronary artery bypass grafting: A prospective observational trial
    (2021)
    Matkovic, Milos (57113361300)
    ;
    Novakovic, Tina (57191900614)
    ;
    Bilbija, Ilija (57113576000)
    ;
    Lazovic, Jelena Milin (57023980700)
    ;
    Tutus, Vladimir (57196079539)
    ;
    Cubrilo, Marko (57209307258)
    ;
    Aleksic, Nemanja (57209310510)
    ;
    Mikic, Aleksandar (57214281171)
    ;
    Petrovic, Emilija (57221497683)
    ;
    Peric, Valerija (57221499377)
    ;
    Milojevic, Aleksandar (57219864196)
    ;
    Putnik, Svetozar (16550571800)
    Background: Preoperative use of platelet function tests contributes to the decrease of re-intervention rate due to bleeding and the necessity of transfusion in coronary artery bypass grafting (CABG) patients. The aim was to investigate the predictive value and to justify routine preoperative use of multiple electrode aggregometry in these patients. Methods: A prospective observational trial which included 416 consecutive patients subjected to elective isolated CABG was conducted. The Multiplate® test was used to assess platelet function. Platelet function test results, postoperative blood loss, and transfusion requirements were compared between high and low bleeding risk patients. Receiver operating characteristic analysis was performed to assess the sensitivity and specificity of the arachidonic acid (ASPI) and adenosine di-phosphate high sensitive (ADPHS) tests. Results: ADPHS and ASPI test results significantly predicted total bleeding > 1000 ml (AUC, 0.685, p <.001; 0.695, p =.039). Sensitivity and specificity were 62.9% and 40.0%, for ADPHS ≤602, and 70.8% and 41.8%, for ASPI ≤ 453. The sensitivity and specificity of cut-off values recommended by the manufacturer were 84.2% and 40.0% for ADPHS ≤ 500, while for ASPI < 600 the values were 54.7% and 62.2%. More platelets and cryoprecipitate were transfused in patients with ADPHS ≤ 602.5 (p <.001; p =.035). Patients with ADPHS ≤ 500 had a higher rate of red blood count, platelet and cryoprecipitate transfusion (p<.001p<.001; p =.013). The manufacturer's ASPI test cut-off values showed no statistically significant prediction for a higher transfusion rate. Conclusion: Preoperative platelet function tests should be conducted systematically for all elective CABG patients who were on dual antiplatelet therapy after adjusting test cut-off values for each population. © 2021 Wiley Periodicals LLC

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback